TRAXENS
19.9.2018 16:02:11 CEST | Business Wire | Press release
TRAXENS today announced that ERCI Eurail Clusters has named TRAXENS DIGITAL FREIGHT TRAIN, Europe's first Freight Train to use an innovative IoT-based system allowing digitalization of operations, the winner of their « Coup de Cœur » Innovation Award. The prize has been given to the company at the InnoTrans 2018 tradeshow in Berlin.
Initially launched with Fret SNCF, the TRAXENS DIGITAL FREIGHT TRAIN solution is based on smart devices capable of communicating with each other using wireless digital network. TRAXENS solution goes beyond smart wagons to connect the entire train offering new high-value-added services.
Inherited from the Shipping Industry, TRAXENS DIGITAL FREIGHT TRAIN has been designed to work worldwide and manage any type of asset (e.g., Dry or Reefer container, wagon, trailer) which means that rail freight can be connected to the rest of the supplier chain anywhere, to explore and leverage door-to-door multimodal applications.
« This industry recognition is a major milestone for us. We have achieved to design and implement with our partner SNCF Logistics such a solution in a two-year timeframe, which has never been experienced in the industry. We are looking forward to extending the solution worldwide, said Florence Delalande, Rail Business Unit Director at TRAXENS.
Dirk-Ulrich Krüger, Spokesperson of the European Railway Clusters Initiative, comments: « We are thrilled to recognize next-generation innovation in the railway industry, and that’s why TRAXENS has earned this award from ERCI Eurail Clusters. Some of the best solutions, come from these kinds of forward-thinking players who think outside of the box. »
The DIGITAL FREIGHT TRAIN innovation enables the stakeholders of the railway ecosystem to share benefits and costs:
Railway undertakings optimise their wagon fleet and streamline operations.
Shippers geolocate their shipments in real-time anywhere around the world and receive alerts when their shipment arrives at key locations
Wagon keepers can use preventive and predictive maintenance based on hard facts (accurate mileage tracking, information on abnormal shocks, brake and axle monitoring).
Customized services are possible: remote control, door opening, temperature and humidity monitoring.
About ERCI Innovation Awards
The ERCI Innovation Awards recognize companies from ERCI partner clusters that have successfully introduced innovative products or solutions to the market. The prize is initiated by the European Railway Clusters Initiative (ERCI).
The categories of the ERCI Innovation Awards are:
- “Best Large Enterprise”
- “Best SME”
- “Coup de Cœur” special jury prize
The term of the award is annually. Hosting of the award ceremony rotates among the ERCI members. The 2018 awarding ceremony was hosted by the Cluster Transport, Mobility and Logistics Berlin-Brandenburg at InnoTrans 2018 on Wednesday, 19 September 2018.
The awarding ceremony, which took place at the Berlin-Brandenburg joint booth in the CityCube, hall B, on Wednesday, 19 September 2018, was organised by the ERCI partner Cluster Transport, Mobility and Logistics in Berlin and Brandenburg with support from Berlin Partner of Business and Technology. The ERCI Innovation Awards Ceremony took place for the fourth time in 2018:
About ERCI
The European Railway Clusters Initiative was founded in 2010 with the signature of the cooperation treaty on InnoTrans 2010. Member clusters of ERCI are:
- I-Trans competitiveness cluster (Famars, France)
- BTS Rail Saxony (Dresden, Germany)
- Cluster Mobilität, Verkehr und Logistik Berlin-Brandenburg, c/o Berlin Partner for Business and Technology (Berlin, Germany)
- CNA Cluster Bahntechnik Bayern (Nuremberg, Germany)
- DITECFER (Pistoia, Italy)
- Inno-Pro (Karup, Denmark)
- Järnvägsklustret (Västeras, Sweden)
- Logistics in Wallonia (Grace-Hollogne, Belgium)
- The Rail Alliance (Birmingham, UK)
- Railgrup (Barcelona, Spain)
- Southern Railway Cluster (Katowice, Poland)
The 11 partner clusters represent more than 1,000 companies from railway industry from all over Europe. ERCI aims aims to promote innovation and the development of new business opportunities as a means of sustainably bolstering competitiveness within the European railway industry. ERCI fosters collaboration between industry and research, initiates innovation projects and organises B2B meetings and workshops. This also includes the promotion of good visibility and networking at EU level.
Projects with participation of ERCI partner clusters include
-
PERES (Promoting European Rail Excellence outSide EU), an ESCP 4i
partnership under the roof of the European Cluster Collaboration
Platform (ESCP).
More information: http://www.peresinfo.com/ - RECORD (Regions in Europe Coordinate and Optimize innovation and competitiveness policy instruments towards improving the sustainability of transport – study case of SMEs in the railway sector). More information: https://www.interregeurope.eu/record/
About TRAXENS :
TRAXENS delivers the world's most exhaustive, precise and timely information about containers in transit anywhere in the world using breakthrough technology and Big Data techniques. This information provides all stakeholders in multi-modal transport the opportunity to improve costs, optimize investment, and offer premium services.
For more information: www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180919005029/en/
Contact:
Press Contact: TRAXENS Geraldine Sauniere, Tel: +33-6-95-91-58-99 Director of Communications g.sauniere@traxens.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom